Active Ingredient History
Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. NCATS
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Breast Neoplasms (Phase 3)
Gallbladder Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Nausea (Phase 2/Phase 3)
Neoplasms (Phase 4)
Reperfusion Injury (Phase 2)
Uterine Cervical Neoplasms (Phase 2/Phase 3)
Vomiting (Phase 2/Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue